Table 4.
Relative changes in efficacy and safety parameters compared with baseline eGFR following treatment with dapagliflozin over 12 weeks
| Parameter | eGFR < 90 ml/min/1.73 m2 (n = 755) | 90 ≤ eGFR < 120 ml/min/1.73 m2 (n = 1164) | eGFR ≥ 120 ml/min/1.73 m2 (n = 107) | P value§ | |||
|---|---|---|---|---|---|---|---|
| Baseline | Δ (95% CI) | Baseline | Δ (95% CI) | Baseline | Δ (95% CI) | ||
| HbA1c (%) | 8.0 ± 1.3 | 4.1 (3.1, 5.2) | 8.1 ± 1.3 | 7.6 (6.9, 8.4) | 8.5 ± 1.6 | 9.5 (6.8, 12.3) | < 0.001 |
| FPG (mg/dl) | 161.0 ± 43.3 | 8.3 (5.9, 10.8) | 167.2 ± 49.5 | 13.3 (11.6, 15.0) | 194.3 ± 64.7 | 17.4 (11.5, 23.4) | 0.001 |
| PPG (mg/dl) | 227.2 ± 75.7 | 6.8 (2.3, 11.2) | 236.4 ± 81.6 | 14.3 (11.0, 17.6) | 252.7 ± 113.1 | 14.5 (− 3.1, 32.0) | 0.024 |
| Weight (kg) | 73.6 ± 13.0 | 3.0 (2.7, 3.2) | 77.0 ± 14.8 | 3.1 (2.9, 3.3) | 84.8 ± 19.9 | 2.0 (1.1, 3.0) | 0.024 |
| SBP (mmHg) | 128.5 ± 14.8 | 1.7 (0.8, 2.5) | 129.3 ± 14.5 | 1.8 (1.2, 2.4) | 130.8 ± 16.2 | 0.4 (− 1.7, 2.5) | 0.457 |
| DBP (mmHg) | 77.3 ± 9.6 | 0.8 (− 0.1, 1.8) | 78.8 ± 10.6 | 1.5 (0.8, 2.2) | 80.9 ± 11.5 | 1.2 (− 1.5, 3.8) | 0.548 |
Δ = [(Baseline value − 12-week value)/(Baseline value)] × 100
eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, FPG fasting plasma glucose, PPG postprandial glucose, SBP systolic blood pressure, DBP diastolic blood pressure
§P value is derived from one-way ANOVA with Bonferroni post hoc analysis